|Videos|February 27, 2017

How Does the Zika Virus Cross the Placenta?

Lenore Pereira, PhD, professor of Cell and Tissue Biology at University of California, San Francisco, discusses how Zika crosses the placenta.

Lenore Pereira, PhD, professor of Cell and Tissue Biology at University of California, San Francisco, discusses how Zika crosses the Placenta.

Interview Transcript (slightly modified for readability)

“Well, we proposed in our publication that the [Zika] virus would come from the maternal bloodstream carried by viremia into the maternal blood space. This is the space between the developing placenta and the decidua. This would be very easy for the virus to do during the first trimester.

We also proposed, based on infections of primary cells from the placenta, and this included amniotic epithelial cells from the amniotic membranes. We discovered that the virus grows very well in this cell type, and even better in cells from mid-gestation rather than late-gestation. It told us that if a person was infected during pregnancy at the time when the baby was getting larger, the parietal decidua, the decidua that lines the uterine wall and comes in close contact with the amniochorionic membranes, [or] the fetal membranes, then the possibility would be that the maternal blood would again infect the trophoblasts in those membranes and then could cross into the fetal compartment and infect the baby in that direction. So, a more direct route in late-gestation could be possible.

Of course, the third possibility, which we didn’t mention in our paper was the possibility that the virus could come from the sexual route, and, again, cross the fetal membranes, because they then abut the access from the vagina— which of course there’s a plug in-between, but still virus might get through. The possibility then, is crossing from the maternal bloodstream, either in the first trimester from the basal decidua, or, at late-gestation through the parietal decidua to the fetal compartment.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.